Audentes Therapeutics (BOLD) Insider Trading & Ownership → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free BOLD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsHeadlinesInsider TradesSocial MediaStock AnalysisAnalyst ForecastsHeadlinesInsider TradesSocial Media Audentes Therapeutics (NASDAQ:BOLD) Insider Buying and Selling ActivityNumber OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$8.20 MNumber OfInsiders Selling(Last 12 Months)0 Get BOLD Insider Trade Alerts Want to know when executives and insiders are buying or selling Audentes Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BOLD Insider Buying and Selling by Quarter Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Audentes Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/2/2024Kristina BurowDirectorBuy200,000$16.00$3,200,000.00 4/2/2024Ra Capital Management, L.P.Major ShareholderBuy312,500$16.00$5,000,000.00 (Data available from 1/1/2013 forward) BOLD Insider Trading Activity - Frequently Asked Questions Who is on Audentes Therapeutics's Insider Roster? The list of insiders at Audentes Therapeutics includes Kristina Burow, and Ra Capital Management, L.P.. Learn more on insiders at BOLD. Which Audentes Therapeutics insiders have been buying company stock? The following insiders have purchased BOLD shares in the last 24 months: Kristina Burow ($3,200,000.00), and Ra Capital Management, L.P. ($5,000,000.00). How much insider buying is happening at Audentes Therapeutics? Insiders have purchased a total of 512,500 BOLD shares in the last 24 months for a total of $8,200,000.00 bought. More Insider Trading Tools from MarketBeat Related Companies: G1 Therapeutics Insider Buying Zevra Therapeutics Insider Buying P3 Health Partners Insider Buying Century Therapeutics Insider Buying Merrimack Pharmaceuticals Insider Buying Puma Biotechnology Insider Buying Adverum Biotechnologies Insider Buying uniQure Insider Buying Emergent BioSolutions Insider Buying Compass Therapeutics Insider Buying Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year This page (NASDAQ:BOLD) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
